J. Mark Sloan MD

Published on 9/22/2025

Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R. Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis-Related Acquired Factor X Deficiency. Am J Hematol. 2025 Sep 22. PMID: 40981270.

Published on 9/16/2025

Parekh A, Lerner A, Thomasson RR, Sloan JM. Incidence of Typical Neutrophil Count With Fy(a-b-) Status Among Hematology Referrals for Neutropenia at an Urban Safety-Net Hospital. Adv Hematol. 2025; 2025:2488148. PMID: 40994727.

Published on 9/2/2025

Avila Rodriguez AM, Hu X, Varga C, Comenzo R, Sarosiek S, Sloan JM, Sanchorawala V, Doros G, Quillen K. Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient. Br J Haematol. 2025 Oct; 207(4):1679-1683. PMID: 40898649.

Published on 6/3/2025

Dittus C, Weinstock MJ, Barnes J, Sandoval-Sus J, Grover NS, Beaven A, Hoye K, Shelton A, Tan X, Srinivasan MD, El-Jawahri A, Sarosiek S, Sloan JM. Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma. Br J Haematol. 2025 Jun 03. PMID: 40459047.

Published on 3/7/2025

Sofoluwe A, Ferri G, Sloan JM, Caron J, Thomasson RR. Implementation of a Duffy antigen screening test order with interpretation guide to help optimize resource allocation at an urban safety-net hospital. Transfusion. 2025 Apr; 65(4):652-653. PMID: 40055154.

Published on 12/10/2024

Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938. PMID: 39348709.

Published on 11/26/2024

Sanchorawala V, Barroso B, Shelton A, Goetz E, Mendelson L, Joshi T, Burke N, Sloan JM, Staron A. Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment. Blood Adv. 2024 Nov 26; 8(22):5826-5828. PMID: 39293090.

Published on 11/22/2024

Reifler KA, Francoeur Smith T, Bodanapu G, Fagan M, Bourque DL, Sloan JM. Indolent infections in patients with hematologic malignancy: A single-center experience screening for tuberculosis and strongyloidiasis prior to cytotoxic therapy in Boston. Leuk Res Rep. 2024; 22:100489. PMID: 39659827.

Published on 9/3/2024

Hibbs SP, Aiken L, Vora K, Mowete C, Merz LE, Apea V, Sloan JM, Lathan CS, Abel GA, Hantel A. Cancer Trial Eligibility and Therapy Modifications for Individuals With Duffy Null-Associated Neutrophil Count. JAMA Netw Open. 2024 Sep 03; 7(9):e2432475. PMID: 39259539.

Published on 3/11/2024

Zheng R, Solomon A, DiLorenzo M, Rajendran I, Park J, Dhongade V, Garcia MA, Eberhardt RT, Sloan JM, Weinberg J, Klings ES. The Association of Anticoagulation Intensity with Outcomes in Hospitalized COVID-19 Patients. Adv Hematol. 2024; 2024:8838308. PMID: 38500844.